Samara Athina A, Boutlas Stylianos, Janho Michel B, Gourgoulianis Konstantinos I, Sotiriou Sotirios
Department of Embryology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.
Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, 41110 Larissa, Greece.
J Pers Med. 2022 Aug 31;12(9):1423. doi: 10.3390/jpm12091423.
Background: Vaccination against SARS-CoV-2 (COVID-19) has become crucial for limiting disease transmission and reducing its severity, hospitalizations and mortality; however, despite universal acceptance, vaccine hesitancy is still significant. In the present manuscript, we aim to assess COVID-19-attributed mortality after the prevalence of new variants of the virus (Delta and Omicron viral strains) and to evaluate the vaccination effect. Methods: All patients that were hospitalized due to COVID-19 infection in the Respiratory Department of a tertiary referral center in central Greece between 1st of June 2021 and 1st of February 2022 were included in the present study. Results: 760 consecutive patients were included in the study; 89 (11.7%) were diagnosed with severe COVID-19 and 220 (38.7%) patients were fully vaccinated. In logistic regression, increased age (aOR = 1.12, p < 0.001), male gender (aOR = 2.29, p = 0.013) and vaccination against SARS-CoV-2 virus (aOR = 0.2, p < 0.001) were associated with mortality attributed to COVID-19 with a statistically significant association. Moreover, increased age (aOR = 1.09, p < 0.001), male gender (aOR = 1.92, p = 0.025) and vaccination against SARS-CoV-2 virus (aOR = 0.25, p < 0.001) were statistically significantly associated with clinical severity of COVID-19 infection. However, when comparing the length of hospitalization between vaccinated and unvaccinated patients, the difference was not statistically significant between the two groups (p = 0.138). Conclusions: Vaccination against SARS-CoV-2 virus had a protective effect in terms of mortality and clinical severity of COVID-19 during the fourth wave of the pandemic in Central Greece. The national vaccination policy has to focus on vulnerable populations that are expected to benefit the most from the vaccine’s protection.
接种严重急性呼吸综合征冠状病毒2(SARS-CoV-2,即新冠病毒)疫苗对于限制疾病传播、减轻疾病严重程度、减少住院率和死亡率至关重要;然而,尽管疫苗已被广泛接受,但疫苗犹豫现象仍然严重。在本论文中,我们旨在评估病毒新变种(德尔塔和奥密克戎毒株)流行后新冠病毒所致的死亡率,并评估疫苗接种效果。方法:纳入2021年6月1日至2022年2月1日期间在希腊中部一家三级转诊中心呼吸科因新冠病毒感染住院的所有患者。结果:本研究共纳入760例连续患者;89例(11.7%)被诊断为重症新冠,220例(38.7%)患者完成了全程接种。在逻辑回归分析中,年龄增加(调整后比值比[aOR]=1.12,p<0.001)、男性(aOR=2.29,p=0.013)和接种新冠病毒疫苗(aOR=0.2,p<0.001)与新冠病毒所致死亡率存在统计学显著关联。此外,年龄增加(aOR=1.09,p<0.001)、男性(aOR=1.92,p=0.025)和接种新冠病毒疫苗(aOR=0.25,p<0.001)与新冠病毒感染的临床严重程度存在统计学显著关联。然而,比较接种疫苗和未接种疫苗患者的住院时长时,两组之间差异无统计学意义(p=0.138)。结论:在希腊中部疫情第四波期间,接种新冠病毒疫苗在新冠病毒所致死亡率和临床严重程度方面具有保护作用。国家疫苗接种政策应聚焦于最有望从疫苗保护中获益的弱势群体。